Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 50
Filter
1.
Jisuanji Fuzhu Sheji Yu Tuxingxue Xuebao/Journal of Computer-Aided Design and Computer Graphics ; JOUR(9):1372-1378, 34.
Article in Chinese | Scopus | ID: covidwho-2090416

ABSTRACT

With the development of computer vision technology, pedestrian trajectory tracking technology pedestrian re-recognition technology has been more and more widely used, and an explicit and accurate representation illustrating the spatial and temporal correlation of a pedestrian’s movement is the key to understanding his/her trajectory in space and time. A scalable visual analytics system called Hi-Geo-Ti is proposed that applies hierachical geographical timelines to allow its users to extract and visualize a pedestrian’s trajectory from a massive storage of images instantaneously. In particular, Hi-Geo-Ti incorporates semantic correlations produced by person re-identification with spatial and temporal attributes of the camera, based on which it creates an interactive combination of 3D trajectory map with 2D plan plot to visually resolve the spatial-temporal entanglement. Taking the transmission process of Covid-19 as case study, by combining with ReID technology, the assistance of proposed visualization system in the fight against the epidemic is demonstrated and user surveys are conducted to verify the effectiveness of proposed design. © 2022 Institute of Computing Technology. All rights reserved.

2.
Applied Ecology and Environmental Research ; JOUR: 4633-4644,
Article in English | Web of Science | ID: covidwho-2082713

ABSTRACT

The coronavirus disease 2019 (COVID-19) is spreading around the world, and Taiwan is no exception. Faced with the outbreak of the epidemic, the Taiwan government immediately ordered a policy of banning indoor dining. The main purpose of the present research is to extend a Theory of Planned Behavior (TPB) and Technology Acceptance Model (TAM) theoretical framework to explore acceptance of sustained utilization behavior of telemedicine in the post-COVID-19 era. An online survey was administered in Taiwan during the COVID-19 pandemic from February 22 to April 6, 2022, and a total of 359 responses were collected by convenience sampling method, and partial least square (PLS) analysis was deployed to examine the hypothesized relationships. The results showed that the sustained utilization behavior of telemedicine had independent significant associations with behavioral intentions;the behavioral intention had independent significant associations with subjective norms, attitudes, perceived behavioral control, perceived usefulness, and perceived ease of use. Moreover, perceived usefulness had independent significant associations with perceived ease of use. This study provides theoretical and practical insights into the psychological and behavioral processes of public use of telemedicine during the post-COVID-19 pandemic, thereby helping policymakers better understand the important developmental implications of telemedicine.

3.
Journal of the Canadian Association of Gastroenterology ; 5, 2022.
Article in English | EMBASE | ID: covidwho-2032068

ABSTRACT

Background: In August 2016 Cortiment® was approved for use in ulcerative colitis (UC) patients in Canada, but not approved for reimbursement;the Canadian Agency for Drugs and Technology in Health cited no comparable benefit for its use over other approved UC medications. Real-world data comparing Cortiment® to other UC medications is limited, especially during the COVID-19 pandemic where the use of steroids is counter-indicated for COVID-19-related outcomes. Aims: To examine the comparative risk of hospitalization, surgery, and infection after initiation of Cortiment® or oral corticosteroids among UC patients using real-world data Methods: Using population-based data from Alberta Canada, two cohorts were compared: 1. Patients dispensed Cortiment® and an ICD diagnostic code for UC [9: 556.X;10: K51.X] (August 1, 2016 to October 31, 2019);and, 2. Validated (algorithm) UC patients dispensed a >30 day supply or >500mg in 24 hours of prednisone/prednisolone (April 1, 2016 to October 31, 2019). All hospitalizations, IBD-surgery, or infections (i.e., pneumonia, c.diff, sepsis, tuberculosis) that occurred 6 or 12 months from initial medication dispensing were identified. Cox-proportional hazard models, with Hazard Ratios (HR), assessed comparative outcomes. Kaplan-Meier survival curves were created, and Poisson regression (or negative binomial) used to assess the Average Monthly Percentage Change (AMPC) with associated 95% confidence intervals (CI). Results: We identified 917 Cortiment® and 2,404 Prednisone patients. Over the study period, prednisone dispensing significantly decreased (AMPC:-2.53% [CI:-2.85,-2.21]) while Cortiment® remained stable. Dispensing of Cortiment® significantly decreased the hazard of hospitalization (all types, except surgery) at 12 months as compared to prednisone, and significantly decreased the hazard of an infection at both 6 and 12 months (Table 1, Fig 1). Conclusions: The use of Cortiment® in a real-world setting is associated with fewer deleterious outcomes, and its use during a pandemic should be preferred, especially when it's counterpart can exacerbate negative COVID-19-related outcomes. (Table Presented).

4.
Journal of the Canadian Association of Gastroenterology ; 4, 2021.
Article in English | EMBASE | ID: covidwho-2032037

ABSTRACT

Background: The COVID-19 pandemic is affecting patients and healthcare providers worldwide. During the first wave of the pandemic, healthcare delivery shifted from in-person to virtual clinics. Non-urgent and some emergent procedures, including endoscopies, surgeries, and imaging, were delayed to limit the spread and divert resources to COVID-19. Aims: To assess the impact of the COVID-19 pandemic in care to IBD patients Methods: A survey study was conducted to assess the impact of the COVID-19 pandemic on IBD care. All patients had a virtual clinic appointment between March to July 2020 at either: University of Alberta Hospital or the University of Calgary Clinic. A section of the survey assessed patient experience of virtual clinics and delays in access to IBD care during the COVID-19 pandemic. Results: A total of 1581 patients were contacted to complete the survey. 628 patients agreed to participate in the survey, however not all patients completed each component. The mean age of patients who participated in the survey was 48 years (SD = 15.19). 408 patients responded to satisfaction/future use questions: 84.3% (344) patients agree/strongly agree they were comfortable communicating to the physician using the remote system, 77.5% (316) of patients agree/strongly agree that virtual clinic is an acceptable way to receive healthcare services, 84.8% (346) of patients agree/strongly agree they would use virtual care services again, and 82.6% (337) agree/strongly agree they were satisfied with the telehealth system. Additional challenges were reported by 228 patients. Fear and stress (infection risk/mental health concerns/unemployment) was reported by 57.4% (131) patients. Access to healthcare services, PPE, and community resources was a challenge experienced by 26.3% (60) patients. Additionally, 16.2% (37) patients experienced uncertainty around IBD-specific care, including procedures, treatments, labs, and medications. Overall, 17.3% of patients reported some type of delay in care by July 2020. Table 1 shows the proportion of patients with a delay by type of care and the median delay: 5.7% of patients with IBD had surgery delayed by a median of 10 weeks (8-16 weeks). Conclusions: While some delays in healthcare delivery occurred during the first wave of the pandemic, overall 82.7% of patients with IBD maintained their care without disruption. Sustaining healthcare delivery to the IBD community required adaptation to virtual care;however, patient satisfaction was overwhelming positive among patients with IBD.

5.
25th International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2021 ; : 969-970, 2021.
Article in English | Scopus | ID: covidwho-2011590

ABSTRACT

Nucleic acid amplification detection is one of the most widely used molecular diagnostic techniques in recent years, which can rapidly and efficiently amplify the characteristic nucleotide sequences of pathogenic bacteria in the diagnosis of infectious diseases, it has been widely used in clinical diagnosis, disease screening and other fields. In this work, we report a micro-cavity digital PCR for rapid detection of pathogens on a silicon-based microfluidic chip. The device has the advantages of high flux, no pumping, rapid reaction, quantification and high sensitivity. © 2021 MicroTAS 2021 - 25th International Conference on Miniaturized Systems for Chemistry and Life Sciences. All rights reserved.

6.
Zhonghua Liu Xing Bing Xue Za Zhi ; 43(8): 1230-1236, 2022 Aug 10.
Article in Chinese | MEDLINE | ID: covidwho-1994238

ABSTRACT

Objective: To investigate the source and the transmission chain of a cold-chain product associated COVID-19 epidemic caused by 2019-nCoV Delta variant in Beijing. Methods: Epidemiological investigation were used to verify the exposure points of the cases. Close contacts were traced from the exposure points, and human and environmental samples were collected for nucleic acid tests. Positive samples were analyzed by gene sequencing. Results: A total of 112 cases of COVID-19 were reported in the epidemic from January 18 to February 6, 2022 in Beijing. Except for 1 case was uncertain, there were epidemiological links among 111 cases. The source of infection was the packages of imported cold-chain products from Southeast Asia, which were harvested and stored in a local cold-storage in January 2021, and packaged and sent to the cold-storage A in A district in June 2021, and then sold in batches in cold-storage B in B district from January 2022. The first case was infected in the handling of positive frozen products, and then 77 cases occurred due to working, eating and living together with the index case in the cold-storage B, cold-storage C and restaurant D. Besides the cold-storage B, C and the restaurant D, there were 16 sub-transmission chains, resulting in additional 35 cases. Conclusion: The epidemic indicated that the risk of 2019-nCoV infection from imported cold-chain products contaminated by package and highlighted the importance to strengthen the management of cold-chain industry in future.


Subject(s)
COVID-19 , Epidemics , Beijing/epidemiology , COVID-19/epidemiology , Humans , SARS-CoV-2
7.
45th Annual International ACM SIGIR Conference on Research and Development in Information Retrieval, SIGIR 2022 ; : 1984-1989, 2022.
Article in English | Scopus | ID: covidwho-1973880

ABSTRACT

Concept drift in stream data has been well studied in machine learning applications. In the field of recommender systems, this issue is also widely observed, as known as temporal dynamics in user behavior. Furthermore, in the context of COVID-19 pandemic related contingencies, people shift their behavior patterns extremely and tend to imitate others' opinions. The changes in user behavior may not be always rational. Thus, irrational behavior may impair the knowledge learned by the algorithm. It can cause herd effects and aggravate the popularity bias in recommender systems due to the irrational behavior of users. However, related research usually pays attention to the concept drift of individuals and overlooks the synergistic effect among users in the same social group. We conduct a study on user behavior to detect the collaborative concept drifts among users. Also, we empirically study the increase of experience of individuals can weaken herding effects. Our results suggest the CF models are highly impacted by the herd behavior and our findings could provide useful implications for the design of future recommender algorithms. © 2022 ACM.

8.
Gastroenterology ; 162(7):S-593-S-594, 2022.
Article in English | EMBASE | ID: covidwho-1967336

ABSTRACT

Background: The immune response of SARS-CoV-2 vaccines is uncertain in those with Inflammatory Bowel Disease (IBD) due to a diverse array of immune-modifying therapies that vary in the mechanism of immunosuppression. Aim: We aimed to quantify the serological response to SARS-CoV-2 vaccines in those with IBD and determine antibody levels across varying therapeutic options. Methods: Individuals with IBD who received a first and/or second dose of a COVID-19 vaccine (Pfizer-BioNTech, Moderna, and/or AstraZeneca) were assessed for serological response (1–8 weeks after first dose;1–8 weeks after second dose, 8–18 weeks after second dose, 18+ weeks after second dose) using the SARS-CoV-2 IgG II Quant assay to the receptor-binding domain of the SARS-CoV-2 spike protein. The cohort was stratified based on age, sex, vaccine received, IBD type, IBD therapeutic, and prior confirmed diagnosis of COVID-19. The primary outcome was seroconversion defined as IgG levels of ³50 AU/mL. Secondarily, we evaluated the geometric mean titer (GMT) with 95% confidence intervals (CI). Results: Table 1 describes the characteristics of individuals with IBD (n=466) with serological data following the first dose (n=247) and/or second dose (n=413) of a COVID-19 vaccine. After 1–8 weeks following first dose of the vaccine, 81.4% seroconverted, with the lowest first-dose conversion rates in patients taking anti- TNF monotherapy (80.3%), anti-TNF combination therapy (51.5%), and corticosteroids (50.0%) (Table 1). Overall, 98.4% of the cohort seroconverted within 1–8 weeks of the second dose. Over time, seropositive rates decreased with 95.8% seroconversion within 8– 18 weeks of the second dose and 90.5% after 18 weeks. Seroconversion after second dose was consistently high across all medication classes (range: 94.6%–100.0%), except for oral corticosteroids (62.5%). GMT levels significantly increased (p<0.0001) from first dose (1825 AU/mL [95% CI: 981, 2668 AU/mL]) to second dose at 1–8 week (9059 AU/mL [7698, 10420 AU/mL]) but fell significantly (p<0.0001) to 3649 AU/mL (95% CI: 2562, 4736 AU/ mL) 8–18 weeks from second dose and 2527 AU/mL (95% CI: 883, 4172 AU/mL) 18+ weeks after second dose (Table 1, Figure 1). GMT levels 1–8 weeks after second dose were higher in those with prior COVID-19 (16,770 AU/mL), but lower in those receiving anti- TNF combination therapy (4231 AU/mL) and oral corticosteroids (5996 AU/mL) (Table 1). Conclusion: Seroconversion rates following full-regimen vaccination are high in patients with inflammatory bowel disease across all medication classes except for anti-TNF combination therapy and oral corticosteroids. Antibody titres and seroconversion rates tend to decrease after eight weeks post-full vaccination, which is consistent across medication classes. (Table Presented) Table 1. Patient and vaccine characteristics, seroconversion rates, and geometric mean titres by prior PCR-confirmed COVID-19 status for each medication class. (Figure Presented) Figure 1. Log-transformed anti-SARS-CoV-2 spike antibody concentration per vaccine category. Black points represent GMTs while narrow black bars represent bounds of 95% CI associated with each GMT. Solid blue line represents threshold for positive seroconversion [ln (50 AU/mL)].

9.
Gastroenterology ; 162(7):S-160-S-161, 2022.
Article in English | EMBASE | ID: covidwho-1967251

ABSTRACT

Background: The immune response to a two-dose regimen of SARS-CoV-2 vaccination in those with Inflammatory Bowel Disease (IBD) has been consistently high in emerging research. Serological responses following a third dose have yet to be established. Aim: We aimed to quantify the serological response to a third dose of SARS-CoV-2 vaccines in those with IBD and compare to responses after a two-dose regimen. Methods: Individuals with IBD who have received at least two doses of a COVID-19 vaccine were assessed for serological response using the SARS-CoV-2 IgG II Quant assay to the receptor-binding domain of the SARSCoV- 2 spike protein at least eight weeks after second dose and then after third dose. The primary outcome was seroconversion defined as IgG levels of ≥50 AU/mL. Secondarily, we evaluated the geometric mean titer (GMT) with 95% confidence intervals (CI). Outcomes were stratified by prior COVID-19 history. A Wilcoxon rank sum test was used to compare antibody titres following 3rd dose vaccination and titres following 2nd dose vaccination. For patients with both post-2nd and post-3rd vaccination serology, the difference in antibody titres between doses was determined and the mean difference was tested using one-sample Student's t-tests. Results: Table 1 describes the characteristics of individuals with IBD (n = 271) with serological data following the corresponding dose for those with 2nd dose vaccination (n = 175) compared to those with a 3rd dose of vaccine (n = 96). Seroconversion following 3rd dose vaccination occurred for all individuals (100.0%), compared to a 94.4% seroconversion rate at least eight weeks following 2nd dose vaccination (range: 8 to 35 weeks post-2nd dose). GMT for the post-3rd dose cohort (16424 AU/mL [13437, 19411 AU/mL]) was significantly higher (p<0.0001) than the post-2nd dose cohort (3261 AU/mL [2356, 4165 AU/mL] (Table 1, Figure 1b). Individual titres as a function of time following 2nd dose vaccination are seen in Figure 1a for both 3rd dose and 2nd dose cohorts. For individuals with serology following both 2nd dose and 3rd dose vaccination (n = 82), seroconversion rates increased from 97.6% to 100.0% after the 3rd dose. GMT following post-3rd dose vaccination also increased with a mean difference in antibody titres between post-3rd dose and post-2nd dose vaccination of 11384 AU/mL (8541, 14228 AU/mL, p < 0.0001). This difference was significant for both individuals with prior COVID-19 history (11682 AU/mL [95% CI: 8618, 14746 AU/mL, p<0.0001]) and individuals without (8194 AU/mL [95% CI: 988, 15400 AU/mL]). Conclusion: Seroconversion rates and antibody response following third dose vaccination are substantially increased as compared to second dose in patients with IBD. Third dose vaccination can counter the decrease in antibody concentration over time following a two-dose regimen. (Table Presented) Table 1. Patient characteristics, vaccine type, seroconversion rates, and geometric mean titres by prior COVID-19 status for post-3rd dose and post-2nd dose cohorts

10.
6th International Conference on Intelligent Transportation Engineering, ICITE 2021 ; 901 LNEE:630-639, 2022.
Article in English | Scopus | ID: covidwho-1899101

ABSTRACT

By 2020, PPI year-on-year growth rate is negative, the CPI year-on-year increase continuously, in the overall economic environment, manufacturing continuous setbacks, at the same time, china automobile industry association information release data said that the auto industry in 2018 negative growth for the first time in ten years and the following two years continued to decline, the following two years continued to decline, the auto industry officially entered the cold winter period, In addition, in the background of Sino-US trade war, COVID-19, to cut overcapacity and inventory in the auto industry, The auto dealer reshuffle trend is obvious, the transformation is imperative, therefore, “Effectively help dealers reduce waste, improve efficiency and collaborate efficiently, promote customer consumption experience and increase transaction frequency and ultimately increase the overall profit of dealers” become the big issue that dealers require to solve immediately, based on the development trend of digital technology and the pain points of current automobile marketing management, the paper propose to improve the business process and marketing management methods of auto 4S shop through digital means, focusing on efficient customer acquisition, precise operation, content marketing and other aspects to adapt to the call of times and maximize profits. © 2022, The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

12.
Zhonghua Liu Xing Bing Xue Za Zhi ; 43(3): 305-309, 2022 Mar 10.
Article in Chinese | MEDLINE | ID: covidwho-1765985

ABSTRACT

Objective: To investigate the epidemiological characteristics and the transmission chain of a family clustering of COVID-19 cases caused by severe acute respiratory 2019-nCoV Delta variant in Changping district of Beijing. Methods: Epidemiological investigation was conducted and big data were used to reveal the exposure history of the cases. Close contacts were screened according to the investigation results, and human and environmental samples were collected for nucleic acid tests. Positive samples were analyzed by gene sequencing. Results: On November 1, 2021, a total of 5 COVID-19 cases caused by 2019-nCoV Delta variant were reported in a family detected through active screening. The infection source was a person in the same designated isolation hotel where the first case of the family cluster was isolated from 22 to 27, October. The first case was possibly infected through aerosol particles in the ventilation duct system of the isolation hotel. After the isolation discharge on October 27, and the first case caused secondary infections of four family members while living together from October 27 to November 1, 2021. Conclusion: 2019-nCoV Delta variant is prone to cause family cluster, and close attention needs to be paid to virus transmission through ventilation duct system in isolation hotels.


Subject(s)
COVID-19 , Epidemics , Aerosols , Humans , SARS-CoV-2
14.
Inflammatory Bowel Diseases ; 28(SUPPL 1):S48, 2022.
Article in English | EMBASE | ID: covidwho-1722441

ABSTRACT

BACKGROUND: The immune response of SARS-CoV-2 vaccines is uncertain in those with Inflammatory Bowel Disease (IBD) due to a diverse array of immune-modifying therapies that vary in the mechanism of immunosuppression. AIM: We aimed to quantify the serological response to SARS-CoV-2 vaccines in those with IBD and determine antibody levels across varying therapeutic options. METHODS: Individuals with IBD who received first and/or second dose of a COVID- 19 vaccine (Pfizer-BioNTech, Moderna, and/or AstraZeneca) were assessed for serological response (2-4 weeks after first dose;2-8 weeks after second dose and 8-18 weeks after second dose) using the SARS-CoV-2 IgG II Quant assay to the spike protein of SARS-CoV-2. The cohort was stratified based on age, sex, vaccine received, IBD type, IBD therapeutic, and prior confirmed diagnosis of COVID-19. The primary outcome was seroconversion defined as IgG levels of ≥50 AU/mL. Secondarily, we evaluated the geometric mean titer (GMT) with 95% confidence intervals (CI). RESULTS: Table 1 describes the characteristics of individuals with IBD (n=464) with serological data following the first dose (n=266) and/or second dose (n=303) of a COVID-19 vaccine. After the first dose of the vaccine, 81.6% seroconverted, with the lowest first-dose conversion rates in patients taking anti-TNF monotherapy (79.7%), anti-TNF combination therapy (52.9%), and corticosteroids (50.0%) (Table 1). Overall, 98.4% of the cohort seroconverted within 2-8 weeks of the second dose, with 94.6% seropositive within 8-18 weeks of the second dose. Seroconversion after second dose was consistently high across all medication classes (range: 94.6%-100.0%), except for oral corticosteroids (62.5%). GMT levels significantly increased (p<0.0001) from first dose (1679 AU/mL) to second dose at 2-8 week (7943 AU/mL) but fell significantly (<0.0001) to 3565 AU/mL 8-18 weeks from second dose (Table 1, Figure 1). GMT levels 2-8 weeks after second dose were higher in those with prior COVID-19 (12,729 AU/mL), but lower in those receiving anti-TNF combination therapy (4231 AU/mL) and oral corticosteroids (5996 AU/mL) (Table 1). CONCLUSION: Seroconversion rates following fullregimen vaccination are high in patients with inflammatory bowel disease across all medication classes except for anti-TNF combination therapy and oral corticosteroids. Antibody titres and seroconversion rates tend to decrease after 8 weeks postfull vaccination, which is consistent across medication classes.

15.
Global Mental Health ; 2022.
Article in English | EMBASE | ID: covidwho-1721250

ABSTRACT

The publisher apologises that upon publication of this article the authors affiliations were not correctly assigned to the authors. The correct listing is as below: Jing Lu1, Min Zhao1,3, Qianying Wu1, Chenyi Ma1, Xiangdong Du2, Xinchuan Lu2, Qiufang Jia2, Chuanwei Li2* 1.Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China 2.Suzhou Guangji Hospital, Affiliated Guangji Hospital of Soochow University, Suzhou, Jiangsu, China 3.Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China The online version of this article has been updated.

16.
2021 ASEE Virtual Annual Conference, ASEE 2021 ; 2021.
Article in English | Scopus | ID: covidwho-1695925

ABSTRACT

A powder compaction system can be useful to various manufacturing technologies. In order to create a powder compaction system, a four-student capstone team is formed with two faculty advisors. This team started their capstone as usual. However, in the middle of the first semester of the capstone (Spring 2020), the team has experienced imposed restrictions due to COVID-19. Restrictions due to COVID-19 were still active in the second semester (Fall 2020). The team could complete the capstone project in Fall 2020 during COVID-19 pandemic. In this paper, the powder compaction system is introduced. The details of the block diagrams and fabricated prototype device are presented. Testing and verifications are shown, and the capstone evaluation is presented. © American Society for Engineering Education, 2021

17.
Annals of Financial Economics ; 2021.
Article in English | Scopus | ID: covidwho-1606304

ABSTRACT

This paper argues on theoretical grounds that the negative oil prices event on April 20, 2020, was mainly due to the strategic interactions among some active traders on both sides of the futures contract. We present a three-player game of futures trading in which a continuum range of negative price can be supported as (strong) Nash equilibrium, yet none of those constitutes an E-equilibrium originally developed by Ma (2009). We further propose the notion of coalition-with-side-payment as a solution concept for the environment where strategic interactions and transfer payments among players are allowed. Our model captures the mechanism underlying futures price manipulation, and its predictions largely agree with the observations on that day, which are beyond the scope of demand-supply and physical delivery narratives. © 2021 World Scientific Publishing Company.

18.
Gastroenterology ; 160(6):S-218, 2021.
Article in English | EMBASE | ID: covidwho-1592623

ABSTRACT

BACKGROUND The COVID-19 pandemic is affecting patients and healthcare providersworldwide. During the first wave of the pandemic, healthcare delivery shifted from inpersonto virtual clinics. Non-urgent and some emergent procedures, including endoscopies,surgeries, and imaging, were delayed to limit the spread and divert resources to COVID-19. AIMS To assess the impact of the COVID-19 pandemic in care to IBD patients METHODSA survey study was conducted to assess the impact of the COVID-19 pandemic on IBDcare. All patients had a virtual clinic appointment between March to July 2020 at either:University of Alberta Hospital or the University of Calgary Clinic. A section of the surveyassessed patient experience of virtual clinics and delays in access to IBD care during theCOVID-19 pandemic. RESULTS A total of 1581 patients were contacted to complete thesurvey. 628 patients agreed to participate in the survey, however not all patients completedeach component. 423 patients reported which hospital they receive their care: 71.2% (301)were from the University of Alberta, 24.6% (104) were from the University of Calgary, and2.9% (18) did not list either hospital. 429 patients provided a postal code, where 71.8%(308) were from either the Calgary or Edmonton metropolitan area. The mean age of patientswho participated in the survey was 48 years (SD = 15.19). 408 patients responded tosatisfaction/future use questions: 84.3% (344) patients agree/strongly agree they were comfortablecommunicating to the physician using the remote system, 77.5% (316) of patientsagree/strongly agree that virtual clinic is an acceptable way to receive healthcare services,84.8% (346) of patients agree/strongly agree they would use virtual care services again, and82.6% (337) agree/strongly agree they were satisfied with the telehealth system. Table 1shows additional challenges experienced by patients. Overall, 17.3% of patients reportedsome type of delay in care by July 2020. Table 2 shows the proportion of patients with adelay by type of care and the median delay: 5.7% of patients with IBD had surgery delayedby a median of 10 weeks (8-16 weeks). Of note, 73.9% (51) of patients were from theUniversity of Alberta, 23.2 (16) were from the University of Calgary, and 2.9% (2) patientsdid not associate with either hospital. Additionally, 75.4% (52) of patients who experienceddelays live within the Calgary/Edmonton metropolitan area. CONCLUSION: While somedelays in healthcare delivery occurred during the first wave of the pandemic, overall 82.7%of patients with IBD maintained their care without disruption. Sustaining healthcare deliveryto the IBD community required adaptation to virtual care;however, patient satisfaction wasoverwhelming positive among patients with IBD.(Table Presented)Table 1: Additional Challenges Experienced by Patients (N = 228)(Table Presented)Table 2: Proportion of IBD Patients with delays in care (N=398)

19.
Zhonghua Yu Fang Yi Xue Za Zhi ; 55(12): 1371-1376, 2021 Dec 06.
Article in Chinese | MEDLINE | ID: covidwho-1600047

ABSTRACT

The Delta variant of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a new global wave of the Coronavirus Disease 2019 (COVID-19) pandemic. COVID-19 vaccines currently available in China show high effectiveness against severe illness and death. However, transmission of the virus is not fully stopped by vaccination alone, therefore, integrated vaccination and non-pharmacological interventions is necessary to prevent and control the epidemic in the near future. Further expanded vaccine coverage of primary doses as well as booster shots in China's domestic population are needed to reduce severe illness and death. In order to provide evidence necessary for adjusting and optimizing immunization strategies and pandemic control measures, it is essential to conduct research on vaccine effectiveness against emerging variants, persistence of vaccine-induced protection, surveillance of adverse event following immunization with large-scale vaccine use, and modelling studies on strategic combinations of vaccination and non-pharmacological interventions.


Subject(s)
COVID-19 , COVID-19 Vaccines , China , Humans , Immunization, Secondary , SARS-CoV-2 , Vaccination
20.
Respirology ; 26(SUPPL 3):50-51, 2021.
Article in English | EMBASE | ID: covidwho-1583452

ABSTRACT

Background and Aims: This study aims to describe the outcomes of evolving treatment regimens among COVID-19 confirmed severe and critical cases admitted at The Lung Center of the Philippines. Methods: A retrospective, cohort study conducted at The Lung Center of the Philippines from March 2020 to August 2020 that included 219 COVID-19 confirmed severe and critical patients. Results: Eleven out of 68 combinations of treatment regimens have significant difference in the proportion of survivors and non-survivors. Number of survivors is greatest for age group 50-59 (p= 0.106). Severe COVID-19 was associated with chronic kidney disease (p= 0.009). Most number of survivors is recorded for regimens with LCP standard of care 2 (antibiotic therapy, multivitamins + zinc, 02 therapy, IV fluid, and management of comorbidities + Anticoagulant + Dexamethasone) and high flow nasal cannula (HFNC). Combinations that included invasive ventilation showed an increased likelihood of death. Regression analysis showed that an increased Apache II score increased the likelihood of death and an increased PF ratio score lessened the probability of death. Median length of hospital stay is 11 days. Conclusions: Treatment regimens that included HFNC and LCP Standard of care 2 in combination with either interferon, tocilizumab, hemoperfusion, proning, or remdesivir decreases the likelihood of death. Invasive ventilation simultaneously given with any of the regimens increases the likelihood of death. Patients with higher Apache II scores and lower Pa02/Fi02 were non-survivors and in a more critical condition.

SELECTION OF CITATIONS
SEARCH DETAIL